VECTICAL (calcitriol) by Galderma is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 2009.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
VECTICAL is a topical ointment formulation of calcitriol, a synthetic active form of vitamin D3 (1,25-dihydroxyvitamin D3), used to treat psoriasis and other dermatological conditions. It works by binding to calcitriol receptors in skin to regulate calcium and phosphorus metabolism and modulate immune/inflammatory pathways. The drug is rapidly absorbed through skin and achieves peak serum concentrations within 3–6 hours, with a pharmacologic duration of 3–5 days.
Limited commercial footprint with modest Part D spending and 9,000 annual claims suggests a mature, niche-market product approaching loss of exclusivity with likely consolidation of team resources.
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on VECTICAL at Galderma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Vitamin D3 Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Oral Calcitriol With Ketoconazole in CRPC
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moVECTICAL offers limited growth opportunity and is currently associated with zero open job postings, reflecting its mature, niche-market status and approaching loss of exclusivity. Career roles on this brand are likely to involve lifecycle management, transition planning, and margin defense rather than launch or expansion activities.